Cypre Status
The company raised $150,000 of convertible debt funding from undisclosed investors on August 24, 2018. Earlier, the company raised an undisclosed amount of venture funding from Hemi Ventures on January 1, 2017.
Developer of a tumor microenvironment system intended to be used for the transformative 3D cellular research and clinical testing of cancer patients. The company's tumor microenvironment system consists of extracellular matrix remodeling, immune infiltration and other processes that influence tumor progression, enabling medical institutions with better and advanced drugs, opening the door for a new generation of therapeutics and patient success.
Year Founded
2016
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Cypre News and Updates
Global Automatic Activation Devices Market 2021 Emerging Players, Growth Analysis And Precise Outlook – 2027 – Bulk Solids Handling
Bulk Solids Handling | September 23, 2021
Tofino Hatchery receives $10K donation – Tofino-Ucluelet Westerly News - Tofino
Tofino-Ucluelet Westerly News | June 15, 2021
Charles River Laboratories taps Cypre for 3D tumor model research
FierceBiotech | February 2, 2021
Sierra school zone extended for Ecole Les Cypres
Medicine Hat News | August 29, 2020
Construction on new École Les Cyprès location reaching final stages
CHAT News Today | July 14, 2020
Cypre's Verticals
Cypre Primary Industry Sector / Group / Code
Cypre's Trends
Cypre Metrics
Majestic Referring Domains
Headquarters
-
HQ Address Line 1953 Indiana Street
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94107
-
HQ CountryUnited States
Cypre's Keywords
mood_badFeed is empty.
Add a review